Related Experiment Videos
CDP-870. Celltech/Pfizer
Stefan Rose-John1, Heidi Schooltink
1Department of Biochemistry, Christian-Albrechts-Universität zu Kiel, 40 Olshausenstrasse, D-24098 Kiel, Germany. rosejohn@biochem.uni-kiel.de
Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2003
Summary
Celltech and Pfizer are developing CDP-870, a PEGylated anti-TNF antibody fragment, for autoimmune diseases like rheumatoid arthritis and Crohn's disease. Phase III trials for rheumatoid arthritis began in 2002, with Crohn's disease trials anticipated in 2003.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Celltech Group plc and Pfizer Inc are collaborating on CDP-870.
- CDP-870 is a polyethylene glycol (PEG)ylated anti-TNF antibody fragment.
- It is being developed for autoimmune and inflammatory diseases.
Purpose of the Study:
- To evaluate the efficacy and safety of CDP-870.
- To potentially treat rheumatoid arthritis (RA) and Crohn's disease (CD).
Main Methods:
- Phase III clinical trials are being conducted.
- Pharmacia initiated trials for RA in October 2002.
- Celltech planned to initiate trials for CD in mid-2003.
Main Results:
- Data on trial outcomes are not yet available in the abstract.
- The abstract focuses on the development and trial status.
Conclusions:
- CDP-870 shows potential for treating RA and CD.
- Further clinical trial data will determine its therapeutic value.